<DOC>
	<DOCNO>NCT00316225</DOCNO>
	<brief_summary>This study test effect pemetrexed mesothelioma non-small cell lung cancer patient fluid around lung abdomen .</brief_summary>
	<brief_title>Study Pemetrexed Mesothelioma Lung Cancer Patients With Fluid Around Lungs Abdomen</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis locally advance metastatic ( Stage III IV entry ) nonsmall cell lung cancer ( NSCLC ) mesothelioma Presence thirdspace fluid ( fluid around lung abdomen ) . Eastern Cooperative Oncology Group Performance Status 0 1 . Prior anticancer treatment ( except radiation ) must complete least 3 week prior study enrollment , patient must recover sharp toxic effect anticancer treatment . Estimated life expectancy least 8 week . Have receive treatment within last 30 day drug market product . Active infection , opinion investigator , would allow patient tolerate therapy . Pregnancy . Breastfeeding . Significant weight loss ( , great equal 10 % body weight ) 6 week study entry . Brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>